Edinburgh, Scotland (April 17, 2024) - Blackford, the pioneering strategic AI platform and solutions provider, and Lucida Medical, a leading developer of AI for cancer imaging, today announced a commercial partnership to bring the Pi™ - Prostate Intelligence™ solution to healthcare professionals via the Blackford Platform.
Blackford provides healthcare professionals access to an extensive portfolio of more than 120 AI solutions designed to drive clinical accuracy and efficiency and improve patient outcomes. By integrating Lucida Medical’s advanced technology into the Blackford Platform, Blackford can offer healthcare providers more powerful tools to support analysis of prostate MRIs.
“Our partnership with Lucida Medical enhances our ability to provide healthcare professionals with AI to help deliver more precise and efficient prostate cancer diagnosis and care.” says Ben Panter, Founder and CEO of Blackford. “We are delighted to integrate the Pi™ solution into our extensive AI portfolio aimed at empowering clinicians with the tools they need to make informed decisions, ultimately improving patient outcomes.”
Prostate cancer is the most common male cancer ¹, with case numbers forecast to double by 2040² and up to 50% of cases currently being diagnosed late, at stages III-IV ³. Pi™ has been designed to help healthcare professionals work more quickly by automating laborious steps, and to increase accuracy for detection of clinically significant prostate cancer.
Dr Antony Rix, Co-Founder and CEO at Lucida Medical, says “Recent research has shown that Pi™ has expert-level performance⁴ in real-world applications across multiple healthcare settings, scanner types and vendors. We are delighted to work with Blackford to offer Pi™ to hospitals across the UK and Europe to help clinical teams save time and offer their patients the best possible diagnosis and treatment for prostate cancer.”